Abstract CT160: A Phase I Trial to Evaluate Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-Grafted Γδ T Cells in Subjects with Advanced Solid Tumors or Hematological Malignancies (the ANGELICA Trial)
Cancer Research（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined